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AbstrACt
Objectives Elevated Lipoprotein(a) (Lp[a]) is a well-known 
risk factor for cardiovascular disease. However, its roles 
in bone metabolism and fracture risk are unclear. We 
therefore investigated whether plasma Lp(a) levels were 
associated with bone mineral density (BMD) and incident 
hip fractures in a large cohort of postmenopausal women.
Design Post hoc analysis of data from the Women’s 
Health Initiative (WHI), USA.
setting 40 clinical centres in the USA.
Participants The current analytical cohort consisted of 
9698 white, postmenopausal women enrolled in the WHI, 
a national prospective study investigating determinants 
of chronic diseases including heart disease, breast and 
colorectal cancers and osteoporotic fractures among 
postmenopausal women. Recruitment for WHI took place 
from 1 October 1993 to 31 December 1998.
Exposures Plasma Lp(a) levels were measured at 
baseline.
Outcome measures Incident hip fractures were 
ascertained annually and confirmed by medical records 
with follow-up through 29 August 2014. BMD at the 
femoral neck was measured by dual X-ray absorptiometry 
in a subset of participants at baseline.
statistical analyses Cox proportional hazards and 
logistic regression models were used to evaluate 
associations of quartiles of plasma Lp(a) levels with hip 
fracture events and hip BMD T-score, respectively.
results During a mean follow-up of 13.8 years, 454 
incident cases of hip fracture were observed. In analyses 
adjusting for confounding variables including age, 
body mass index, history of hysterectomy, smoking, 
physical activity, diabetes mellitus, general health status, 
cardiovascular disease, use of menopausal hormone 
therapy, use of bisphosphonates, calcitonin or selective-
oestrogen receptor modulators, baseline dietary and 
supplemental calcium and vitamin D intake and history 
of fracture, no significant association of plasma Lp(a) 
levels with low hip BMD T-score or hip fracture risk was 
detected.
Conclusions These findings suggest that plasma Lp(a) 
levels are not related to hip BMD T-score or hip fracture 
events in postmenopausal women.
trial registration number NCT00000611; Post-results.
IntrODuCtIOn 
Lipoprotein(a) [Lp(a)] is a plasma lipopro-
tein consisting of a cholesterol-rich low-den-
sity lipoprotein (LDL)-like particle having 
one molecule of apolipoprotein B100 and 
an additional protein, apolipoprotein(a), 
attached to apoB via a disulfide bond. Vari-
ability of Lp(a) is mainly genetically deter-
mined with similar levels in men and women 
but differences among races.1 Elevated 
Lp(a) plasma levels have been identified to 
be an independent risk factor for cardio-
vascular events and aortic valve stenosis.2 
The mechanisms of how elevated Lp(a) 
lead to adverse cardiac outcomes are not 
completely understood, but several mech-
anisms and theories have been proposed.3 4 
Among the most accepted, Lp(a) because of 
its structural/functional homology to plas-
minogen competes with plasminogen and 
impairs fibrinolysis and pericellular proteol-
ysis. Moreover, elevated Lp(a) concentration 
may not only decrease fibrinolytic activity, it 
may also prolong plasminogen activation by 
preventing the irreversible inhibition of the 
plasminogen activators.5 
There is accumulating evidence that Lp(a) 
and plasminogen, besides their roles in 
strengths and limitations of this study
 ► Large, geographically diverse prospective cohort 
with long duration of follow-up.
 ► Detailed assessment of risk factors for fracture 
events and physician-adjudicated information on 
hip fractures was available.
 ► The analysis was restricted to white postmenopaus-
al women and thus generalisability is limited.
 ► No information on apolipoprotein(a) size was 
available.
 ► Residual confounding cannot be excluded.
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haemostasis and cardiovascular disease, may also be essen-
tial for tissue repair. Plasminogen deficiency has been 
recently shown to inhibit fracture repair and adequate 
fibrinolysis is increasingly regarded as an emerging target 
to fracture healing.6 It is therefore plausible that Lp(a) 
plasma levels may also contribute to healing processes 
and remodelling from traumas or injuries. Furthermore, 
elevated Lp(a) plasma levels have been associated with 
aortic valve stenosis as well as chronic kidney disease, both 
of which increase the likelihood of syncopal episodes, 
falls and decreased bone mineral density (BMD).7 8
To this date, evidence on the associations between 
Lp(a) and BMD is sparse, and prior findings have been 
conflicting.9 10 To our knowledge, no previous study has 
investigated the association between Lp(a), BMD and hip 
fracture risk. We thus aimed to investigate if Lp(a) levels 
are associated with hip BMD T-scores and hip fracture 
events in a large cohort of white postmenopausal women 
with long-term follow-up. 
MEthODs
study population
The study population consisted of women enrolled in the 
Women’s Health Initiative (WHI). WHI is a long-term 
health study that has focused on strategies for preventing 
heart disease, breast and colorectal cancers, and osteo-
porotic fractures in postmenopausal women.11 It has two 
major parts: a clinical trial (CT) and an observational 
study (OS). Recruitment to WHI was conducted by 40 
participating clinical sites nationwide in the USA and 
took place from 1 October 1993 to 31 December 1998, 
using such methods as media advertising, direct popu-
lation mailing, community lectures and public service 
announcements, and celebrity endorsements. Women 
were eligible to participate if 50–79 years of age and 
postmenopausal at the time of enrolment. In addition to 
age and menopausal status, women were generally free 
of recent serious cardiac, pulmonary, renal and hepatic 
conditions and had at least 3 years of life expectancy. The 
WHI OS examined the predictors and natural course of 
important causes of morbidity and mortality in postmeno-
pausal women. The three WHI CTs tested several inter-
ventions among postmenopausal women: a low-fat eating 
pattern, menopausal hormone therapy and calcium and 
vitamin D supplementation. Institutional review boards 
(IRBs) of all participating institutions (40 clinical site 
IRBs, the coordinating centre IRB and ethical review at 
National Institutes of Health) approved all protocols and 
all participants provided written informed consent.
Lp(a) levels
A subsample of women enrolled in WHI, randomly 
selected at baseline, provided fasting blood specimens at 
baseline which were collected following a standardised 
protocol.11 Blood samples were labelled, centrifuged and 
frozen on site in −70°C freezers and later shipped to the 
central WHI specimen repository. Lp(a) was quantitated 
using an isoform independent bi-site ELISA assay proce-
dure based on the linkage of apo(a) to apoB.12Stan-
dardisation and ongoing quality control was established 
and maintained with Northwest Lipid Research Clinic. 
Throughout the study, the laboratory participated in 
and remained certified by the National Heart, Lung, 
and Blood Institute, Centers for Disease Control Part III 
programme.13 As Lp(a) levels vary by race and due to 
a limited number of non-white participants to reliably 
examine associations, we limited this analysis to white 
participants who were followed up through 29 August 
2014 (n=9698).
Outcomes
The primary outcome measure was incident hip fracture 
events. Information regarding incident fractures was 
determined by self-report semiannually through the end 
of the WHI CTs and annually when the trials finished. 
In the WHI OS, fractures were self-reported annu-
ally. All self-reported hip fractures were subsequently 
confirmed by medical record review by blinded physician 
adjudicators.11
Covariate assessment
Information on age, personal history of fracture, smoking 
status, physical activity and general health status were 
obtained by self-report questionnaires at baseline.11 
Trained clinic staff measured weight and height at base-
line using standardised protocols. Body mass index 
(BMI) was calculated as weight in kilograms divided by 
the square of the height in metres. Current medication 
or supplement use was assessed at baseline by clinic inter-
viewers. Diabetes status was determined by self-reported 
physician diagnosis of diabetes treated with either oral 
medication or insulin. Cardiovascular Disease (CVD) was 
defined as a reported history of cardiovascular disease, 
myocardial infarction, stroke, transitory ischaemic attack, 
angina or revascularisation. BMD at the femoral neck 
was measured by dual X-ray absorptiometry (QDR 2000, 
2000+ or 4500W, Hologic, Massachusetts, USA) in a subset 
of WHI participants (WHI-BMD cohort) at 3 of the 40 US 
clinical centres (Pittsburgh, Pennsylvania; Birmingham, 
Alabama; and Tucson/Phoenix, Arizona, USA) at base-
line (n=758).11 For this analysis, BMD T-scores were based 
on the Third National Health and Nutrition Examination 
Survey (NHANES III) reference database. 
statistics
Baseline characteristics across quartiles of Lp(a) plasma 
levels were compared using χ2 statistics for categorical vari-
ables and ANOVA, as appropriate, for continuous variables. 
HRs for risk of hip fracture associated with quartiles of 
Lp(a) were obtained using covariate-adjusted Cox propor-
tional hazards models. Among women who experienced a 
fracture event, duration of follow-up was defined as time to 
first fracture. Among women who did not experience a frac-
ture during follow-up, duration of follow-up was defined 
as time until last follow-up visit, or death, whichever came 
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first. Three models were formed to examine the effect of 
potential confounding: Model 1 included age and BMI 
as covariates. Model 2 additionally adjusted for WHI CT 
assignment, smoking, physical activity, diabetes mellitus, 
history of fracture on or after age 55, general health status, 
baseline dietary and supplemental vitamin D intake, 
baseline dietary and supplemental calcium intake, use of 
menopausal hormone therapy (by self-report OS or by CT 
randomisation), use of bisphosphonates, calcitonin, or 
selective-oestrogen receptor modulators. Model 3 adjusted 
for all variables in Model 2 and additionally for history of 
CVD and history of hysterectomy. Continuous predictors 
were handled as if linear except for vitamin D and calcium 
intake, which were categorised (<200, 200-<400, 400-<600 
and ≥600 IU/day for vitamin D and <800, 800-<1200 
or ≥1200 mg/day for calcium). Using the aforementioned 
modelling approach, we used logistic regression models to 
examine the associations of Lp(a) plasma levels with hip 
BMD T-score, categorised as either normal BMD (T-score 
≥−1) and low BMD (T-score <-1) in the analysis. The refer-
ence category for the outcome in this analysis was normal 
BMD (T-score ≥ −1). Finally, we examined the association 
of quartiles of Lp(a) plasma levels with risk of any non-hip 
fracture event using Cox proportional hazards regression 
models. Statistical analyses were conducted using SAS V.9.4.
sample size calculation
To our knowledge, data on the association between Lp(a) 
plasma levels and risk of hip fractures are missing. Our 
study population consisted of 9698 women with Lp(a) 
measurements; 454 incident cases of hip fractures were 
documented. The sample size was sufficient to detect a 
HR of greater than 1.3 with 80% power at a two-sided 
significance level of α=0.05 for a two group comparison.
Patient and public involvement
WHI was designed to address the gaps in knowledge 
about the major health issues in postmenopausal women. 
Patients assisted research staff in recruiting, and results 
for all measures done at the study examinations were 
explained to each participant. Major study results were 
communicated to participants via newsletters.
rEsuLts
The overall analytic sample consisted of 9698 women. 
Across quartiles of Lp(a), women were approximately the 
Table 2 HRs for incident hip fracture events by quartiles of Lp(a) plasma levels
Quartiles (Q)
Median Lp(a) 
mg/dL
No of 
individuals No of cases HR (95% CI)* HR (95% CI)† HR (95% CI)‡ 
Q1 3 2431 113 1 1 1
Q2 10 2327 105 0.97 (0.75 to 1.27) 0.93 (0.71 to 1.22) 0.92 (0.70 to  1.22)
Q3 20 2500 122 1.06 (0.82 to 1.37) 0.99 (0.76 to  1.29) 0.98 (0.75 to  1.28)
Q4 59 2440 114 1.05 (0.81 to 1.36) 0.99 (0.76 to  1.30) 0.99 (0.76 to  1.30)
P trend 0.60 0.93 0.94
*Model 1 adjusted for linear age and BMI.
†Model 2 additionally adjusted for WHI CT assignment, smoking, physical activity, diabetes mellitus, general health status, history of fracture, 
baseline dietary and supplemental vitamin D intake, baseline dietary and supplemental calcium intake, use of menopausal hormone therapy 
and use of bisphosphonates, calcitonin or selective-oestrogen receptor modulators.
‡Model 3 adjusted for Model two and additionally for history of hysterectomy and CVD.
BMI, body mass index; CVD, Cardiovascular Disease; Lp(a), lipoprotein(a); WHI, Women’s Health Initiative. 
Table 3 ORs for low bone mineral density (T-score <−1.0) by quartiles of Lp(a) plasma levels
Quartiles (Q)
Median Lp(a) 
mg/dL
No. of 
individuals No. of cases OR (95% CI)* OR (95% CI)† OR (95% CI)‡ 
Q1 3 175 80 1 1 1
Q2 10 193 95 1.16 (0.74 to 1.84) 1.27 (0.77 to  2.09) 1.27 (0.77 to  2.09)
Q3 20 188 96 1.52 (0.96 to 2.42) 1.60 (0.96 to  2.66) 1.60 (0.96 to  2.66)
Q4 59 202 102 1.30 (0.83 to 2.06) 1.36 (0.81 to  2.26) 1.35 (0.81 to  2.25)
P trend 0.16 0.17 0.17
The reference category for the outcome in this analysis was normal BMD (T-score ≥−1).
*Model 1adjusted for linear age and BMI.
†Model 2additionally adjusted for WHI CT assignment, smoking, physical activity, diabetes mellitus, general health status, history of fracture, 
baseline dietary and supplemental vitamin D intake, baseline dietary and supplemental calcium intake, use of menopausal hormone therapy 
and use of bisphosphonates, calcitonin or selective-oestrogen receptor modulators.
‡Model 3 adjusted for Model two and additionally for history of hysterectomy and CVD.
BMD, bone mineral density; BMI, body mass index; CVD, Cardiovascular Disease; Lp(a), lipoprotein(a); WHI, Women’s Health Initiative. 
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same age (67 years) and slightly overweight (mean BMI 
27 kg/m2) (table 1). Furthermore, there were no marked 
differences in history of diabetes, general health, history 
of CVD, history of fracture on or after age 55, smoking or 
physical activity. Women with Lp(a) in the lower quartiles 
were more likely to use menopausal hormone therapy 
and to have had a history of hysterectomy compared with 
women with high plasma Lp(a). The use of bisphospho-
nates, calcitonin and selective oestrogen receptor modu-
lators was low. No clinically significant differences in hip 
BMD were found across Lp(a) quartiles.
Included women (WHI-OS and WHI-CT) were followed 
for a mean (SD) of 13.8 years (5.8); women in the WHI-OS 
were followed for 13.3 years (5.7); women in WHI-CT were 
followed for 14.7 years (5.8) (p<0.0001). There were 454 
cases of hip fractures in the overall analytic sample. No 
significant associations between quartiles of plasma Lp(a) 
levels and hip fractures were detected (table 2). Further, 
there were no significant associations between Lp(a) 
plasma levels and hip BMD T-score (table 3). Finally, no 
association between quartiles of plasma Lp(a) levels and 
any non-hip fracture event was seen (table 4).
DIsCussIOn
Our results based on a large population of white post-
menopausal women suggest that plasma Lp(a) levels 
are not associated with BMD T-score or hip fracture 
risk. These findings complement prior epidemiological 
studies on the associations of lipid and lipoproteins with 
BMD and fracture risk.14–20
Higher triglyceride or LDL cholesterol levels in midlife 
and in postmenopausal women have been associated with 
increased fracture risk.14 15 Moreover, some authors reported 
a modest, inverse relationship between lumbar spine and 
whole body BMD with serum triglyceride and LDL levels 
in postmenopausal women and HDL in premenopausal 
women but overall data on the relationship between lipid 
profiles and BMD are conflicting.16–20 Meta-analyses of 
randomised controlled trials found lipid-lowering thera-
pies to be associated with significant increases in BMD but 
not associated with fracture risk.21 Little is known on the 
associations between Lp(a) and BMD.9 10 Elevated Lp(a) 
plasma levels have been associated with lower BMD in 
early postmenopausal overweight women in some popu-
lations but questions remain.9 These questions involve 
inter alia the concurrent use of hormone therapy as well 
as concomitant chronic disease: Oestrogen but not addi-
tion of progestogen has been shown to lower plasma Lp(a) 
levels most likely due to a reduction in the rate of apolipo-
protein(a) synthesis.22 This is clinically relevant as the rela-
tionship of elevated Lp(a) levels with cardiovascular disease 
risk has been further shown to be modified by oestrogen 
therapy and that the predictive utility of Lp(a) was mark-
edly attenuated among women taking oestrogen.23 On the 
other hand, an increase in Lp(a) concentrations is seen in 
non-nephrotic patients  with primary renal disease even in 
the earliest stage when GFR is not yet subnormal.8 Elevated 
Lp(a) levels have been shown to be associated with aortic 
valve stenosis in a large Danish cohort.7 As aortic valve 
stenosis increases the likelihood of syncopal episodes, an 
increased fracture risk may be the consequence. Our results 
show a higher prevalence of hormone therapy use among 
women in the lower quartiles of Lp(a) plasma levels but 
no clinically meaningful differences in hip T-scores across 
Lp(a) quartiles. We also did not see any association of Lp(a) 
with low BMD T-score. Moreover, after adjusting for a wide 
range of confounding factors, we did not find any asso-
ciation of Lp(a) plasma levels with either hip fracture or 
non-hip fracture events.
Strengths of this study include a long duration of 
follow-up, detailed information regarding risk factors for 
fracture events and adjudicated information regarding hip 
fractures. Nonetheless, there are several limitations. First, 
our analysis was restricted to white postmenopausal women, 
thus, generalisability is limited. Second, we are lacking infor-
mation on kidney function and on apolipoprotein(a) size. 
Smaller apolipoprotein(a) isoforms and higher Lp(a) levels 
have been linked to incident cardiovascular disease, but 
their independent contributions are less clear.24 25 Third, 
due to the observational character of this study, although 
Table 4 HRs for incident non-hip fracture events by quartiles of Lp(a) plasma levels
Quartiles (Q)
Median Lp(a) 
mg/dL
No of 
individuals* No of cases HR (95% CI)† HR (95% CI)‡ HR (95% CI)§ 
Q1 3 2418 711 1 1 1
Q2 10 2319 636 0.92 (0.82 to  1.02) 0.88 (0.79 to  0.99) 0.88 (0.79 to  0.98)
Q3 20 2493 773 1.05 (0.94 to  1.16) 1.00 (0.90 to  1.11) 0.99 (0.89 to  1.11)
Q4 59 2428 687 0.96 (0.86 to  1.06) 0.91 (0.81 to  1.01) 0.90 (0.81 to  1.01)
P trend 0.99 0.33 0.98
*Missing information on 40 individuals.
†Model 1 adjusted for linear age and BMI.
‡Model 2 additionally adjusted for WHI CT assignment, smoking, physical activity, diabetes mellitus, general health status, history of fracture, 
baseline dietary and supplemental vitamin D intake, baseline dietary and supplemental calcium intake, use of menopausal hormone therapy 
and use of bisphosphonates, calcitonin or selective-oestrogen receptor modulators.
§Model 3 adjusted for Model two and additionally for history of hysterectomy and CVD.
BMI, body mass index; CVD, Cardiovascular Disease; WHI, Women’s Health Initiative. 
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our analyses included women who were generally healthy at 
baseline, residual confounding cannot be excluded. Finally, 
although our sample size was large, our study may have 
lacked power to detect small differences.
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